| Name | Faron Pharmaceuticals Oy (DI) |
|---|---|
| Epic | FARN |
| Isin | FI4000153309 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 143.33p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £149.96 | Debt ratio | n/a |
| Shares in issue | 72.01 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 910.39 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -48 | 52-week high / low | 92.50p / 350.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Faron Pharmaceuticals Oy (DI) |
|---|---|
| Address | Joukahaisenkatu 6, Turku, Finland, FI-20520 |
| Telephone | +358 2 469 5151 |
| Website | http://www.faronpharmaceuticals.com |
| Director | Position |
|---|---|
| Dr Juho Jalkanen | CEO |
| Mr Tuomo Pätsi | Chairman |
| Ms Christine Roth | Non-Executive Director |
| Mr Marie-Louise Fjällskog | Non-Executive Director |
| Dr Markku Jalkanen | Director |
| Mr John Poulos | Independent Non-Executive Director |
| Assets € (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 1.09 | 1.15 | 0.9 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 1.35 | 1.54 | 1.16 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 1.99 | 2.74 | 5.17 |
| Cash and equivalents | 6.88 | 6.99 | 6.85 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 10.22 | 11.27 | 13.18 |
| Liabilities € (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 15.01 | 10.47 | 7.18 |
| Long term liabilities | 10.37 | 12.28 | 3.09 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 25.38 | 22.75 | 10.26 |
| Net assets € (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | -15.16 | -11.48 | 2.92 |
| Equity € (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 2.69 | 2.69 | 2.69 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -172.21 | -143.71 | 116.51 |
| Share premium account | n/a | n/a | n/a |
| Total equity | -15.16 | -11.48 | 2.92 |
| Income € (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -28.57 | -27.43 | -21.11 |
| Pre-tax profit | -30.94 | -28.73 | -21.18 |